DVAX Dynavax Technologies Corp

Price (delayed)

$11.39

Market cap

$1.49B

P/E Ratio

162.71

Dividend/share

N/A

EPS

$0.07

Enterprise value

$1.61B

Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of ...

Highlights
DVAX's quick ratio has soared by 66% YoY and by 9% QoQ
DVAX's gross margin is up by 26% YoY and by 2.4% QoQ
The company's gross profit has shrunk by 55% YoY but it rose by 4.2% QoQ
DVAX's EPS has plunged by 96% YoY
The net income has dropped by 96% year-on-year

Key stats

What are the main financial stats of DVAX
Market
Shares outstanding
130.89M
Market cap
$1.49B
Enterprise value
$1.61B
Valuations
Price to book (P/B)
2.41
Price to sales (P/S)
6.28
EV/EBIT
110.16
EV/EBITDA
72.58
EV/Sales
6.82
Earnings
Revenue
$236.15M
EBIT
$14.62M
EBITDA
$22.19M
Free cash flow
$53.69M
Per share
EPS
$0.07
Free cash flow per share
$0.41
Book value per share
$4.74
Revenue per share
$1.81
TBVPS
$7.56
Balance sheet
Total assets
$986.57M
Total liabilities
$368.09M
Debt
$251.54M
Equity
$618.48M
Working capital
$795.28M
Liquidity
Debt to equity
0.41
Current ratio
15.2
Quick ratio
13.74
Net debt/EBITDA
5.39
Margins
EBITDA margin
9.4%
Gross margin
80.3%
Net margin
3.9%
Operating margin
-10.4%
Efficiency
Return on assets
0.9%
Return on equity
1.5%
Return on invested capital
1.5%
Return on capital employed
1.6%
Return on sales
6.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DVAX stock price

How has the Dynavax Technologies stock price performed over time
Intraday
1.7%
1 week
9.31%
1 month
1.61%
1 year
-19.79%
YTD
-18.53%
QTD
1.42%

Financial performance

How have Dynavax Technologies's revenue and profit performed over time
Revenue
$236.15M
Gross profit
$189.73M
Operating income
-$24.55M
Net income
$9.22M
Gross margin
80.3%
Net margin
3.9%
The company's operating margin has shrunk by 131% YoY but it rose by 35% QoQ
DVAX's operating income has dropped by 111% year-on-year but it is up by 34% since the previous quarter
The net income has dropped by 96% year-on-year
Dynavax Technologies's net margin has plunged by 89% YoY

Growth

What is Dynavax Technologies's growth rate over time

Valuation

What is Dynavax Technologies stock price valuation
P/E
162.71
P/B
2.41
P/S
6.28
EV/EBIT
110.16
EV/EBITDA
72.58
EV/Sales
6.82
DVAX's EPS has plunged by 96% YoY
DVAX's P/B is 79% below its 5-year quarterly average of 11.1 and 18% below its last 4 quarters average of 2.9
Dynavax Technologies's equity has increased by 10% YoY
DVAX's revenue has dropped by 64% year-on-year
The P/S is 14% less than the 5-year quarterly average of 7.2 but 4.7% more than the last 4 quarters average of 5.9

Efficiency

How efficient is Dynavax Technologies business performance
The ROE has plunged by 97% YoY
Dynavax Technologies's ROA has plunged by 96% YoY
Dynavax Technologies's return on invested capital has shrunk by 95% YoY
DVAX's ROS has plunged by 83% YoY

Dividends

What is DVAX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DVAX.

Financial health

How did Dynavax Technologies financials performed over time
Dynavax Technologies's total assets is 168% higher than its total liabilities
Dynavax Technologies's current ratio has surged by 68% YoY and by 10% QoQ
DVAX's quick ratio has soared by 66% YoY and by 9% QoQ
Dynavax Technologies's debt is 59% less than its equity
Dynavax Technologies's equity has increased by 10% YoY
The debt to equity has contracted by 9% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.